A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors

Trial Profile

A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs AL 101 (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top